.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Johnson and Johnson
Covington
AstraZeneca
Chinese Patent Office
Colorcon
Cantor Fitzgerald
Julphar
Medtronic
Fuji

Generated: December 15, 2017

DrugPatentWatch Database Preview

Claims for Patent: 6,479,500

« Back to Dashboard

Claims for Patent: 6,479,500

Title: Agents for alleviating side effects
Abstract:The present invention provides an agent for alleviating side effects caused by use of an anti-tumor agent, which contains 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidi nedione (1) represented by formula (1): ##STR1## or a pharmaceutically acceptable salt thereof. The 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione or a pharmaceutically acceptable salt thereof exhibit an inflammatory-suppressing action in the digestive tract and advantageously alleviate diarrhea and loss of body weight concomitant with administration of a chemical for treating cancer without suppressing the anti-tumor effect. Thus, the compounds of the present invention are of great value as agents for alleviating side effects caused by use of an anti-tumor agent, which enable not only the chemotherapy to be continuedly carried out, but also the body exhaustion to be effectively prevented.
Inventor(s): Fukushima; Masakazu (Hannou, JP), Yamamoto; Noriyuki (Sayama, JP), Suzuki; Norihiko (Hidaka, JP)
Assignee: Taiho Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:09/701,041
Patent Claims: 1. A method for alleviating side effects caused by use of an anti-tumor agent comprising administering 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione represented by formula (1): ##STR3##

or a pharmaceutically acceptable salt thereof to a patient to whom an anti-tumor agent has been administered.

2. A method according to claim 1, wherein the side effect caused by use of the anti-tumor agent is nausea, vomiting, diarrhea, anorexia, or loss of body weight.

3. A method according to claim 1 or 2, wherein the anti-tumor agent is an antimetabolite, an alkylating agent, a plant-derived compound, an antibiotic, or a platinum-containing agent.

4. A method according to claim 1 or 2, wherein the anti-tumor agent is 5-trifluoromethyl-2'-deoxyuridine, 5-fluorouracil, irinotecan hydrochloride, or cisplatin.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Accenture
QuintilesIMS
Cantor Fitzgerald
Express Scripts
Mallinckrodt
Dow
Argus Health
Federal Trade Commission
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot